Floatz logo

n-803

FIGO Stage III and IV Ovarian Cancer

Masonic Cancer Center, University of MinnesotaPhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

245 Active assets in the FIGO Stage III and IV Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

n-803 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
52 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →